In the phase II study , 12 patients were randomized to receive obatoclax at the dose identified during phase I ( 3 h 3 d ) or 60 mg/day administered by continuous infusion over 24 hours for 3 days ( 24 h 3 d ) to determine the morphologic complete response rate .